LeonaBio (LONA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
11 May, 2026Executive summary
Annual meeting scheduled for June 22, 2026, with virtual participation available for shareholders.
Shareholders are encouraged to review proxy materials and vote by June 21, 2026, 11:59 PM ET.
Voting matters and shareholder proposals
Election of three Class III directors: Kelly A. Romano, James A. Johnson, and Natalie Holles, with board recommending a vote for all.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote to approve named executive officer compensation, with board recommending approval.
Advisory vote on the frequency of future stockholder advisory votes on executive compensation.
Board of directors and corporate governance
Board recommends all director nominees for election to Class III positions.
Latest events from LeonaBio
- Net loss rose to $52.0M as cash fell to $51.1M, with urgent need for additional funding.LONA
Q2 2026 - All proposals passed, directors reelected, and no shareholder questions were raised.LONA
AGM 2026 - Proxy covers director elections, auditor ratification, compensation, and ESG oversight.LONA
Proxy filing - Q1 2026 net loss rose to $32.9M as R&D spending increased; cash covers 12 months, more funding needed.LONA
Q1 2026 - Lasofoxifene plus abemaciclib shows strong promise for ESR1-mutated metastatic breast cancer.LONA
Status update - Registering 5.5M shares for resale; proceeds from warrant exercise support drug pipeline.LONA
Registration filing - 58.5M shares registered for resale; warrant exercises could yield over $146M for clinical programs.LONA
Registration filing - Secured lasofoxifene license, raised $90M, and advanced clinical pipeline amid higher R&D spend.LONA
Q4 2025 - All proposals, including key share issuances and governance changes, were approved by majority vote.LONA
EGM 2026